$74.1 Million is the total value of CAXTON CORP's 19 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 73.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNTA | Buy | SYNTA PHARMACEUTICALS CORP | $64,500,000 | -22.0% | 37,069,140 | +0.0% | 87.00% | -0.5% |
| CPXX | CELATOR PHARMACEUTICALS INC | $3,729,000 | -25.9% | 2,246,469 | 0.0% | 5.03% | -5.6% | |
| DNAI | New | PRONAI THERAPEUTICS INC | $938,000 | – | 45,719 | +100.0% | 1.26% | – |
| ACAS | Sell | AMERICAN CAP LTD | $894,000 | -13.7% | 73,558 | -3.8% | 1.21% | +10.0% |
| IVTY | INVUITY INC | $475,000 | -0.8% | 33,905 | 0.0% | 0.64% | +26.4% | |
| GDX | New | MARKET VECTORS ETF TRcall | $436,000 | – | 31,733 | +100.0% | 0.59% | – |
| NSL | Buy | NUVEEN SR INCOME FD | $417,000 | +109.5% | 70,518 | +126.4% | 0.56% | +166.4% |
| PHD | Sell | PIONEER FLOATING RATE TR | $369,000 | -11.5% | 32,637 | -10.9% | 0.50% | +12.9% |
| SLRC | New | SOLAR CAP LTD | $318,000 | – | 20,098 | +100.0% | 0.43% | – |
| EVF | Buy | EATON VANCE SR INCOME TRsh ben int | $310,000 | +1.0% | 52,889 | +6.9% | 0.42% | +28.6% |
| FRA | Buy | BLACKROCK FLOAT RATE OME STR | $309,000 | +107.4% | 23,888 | +117.3% | 0.42% | +163.9% |
| JRO | New | NUVEEN FLTNG RTE INCM OPP FD | $281,000 | – | 28,207 | +100.0% | 0.38% | – |
| MDLY | Buy | MEDLEY MGMT INC | $233,000 | -30.0% | 35,259 | +25.2% | 0.31% | -10.8% |
| MCC | Sell | MEDLEY CAP CORP | $216,000 | -24.5% | 29,089 | -9.3% | 0.29% | -4.0% |
| SCM | New | STELLUS CAP INVT CORP | $213,000 | – | 21,155 | +100.0% | 0.29% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $155,000 | +2.6% | 23,035 | +31.2% | 0.21% | +30.6% |
| CMFN | New | CM FIN INC | $150,000 | – | 14,658 | +100.0% | 0.20% | – |
| SNTA | Buy | SYNTA PHARMACEUTICALS CORPcall | $99,000 | -14.7% | 57,000 | +9.6% | 0.13% | +8.9% |
| FSC | New | FIFTH STREET FINANCE CORP | $98,000 | – | 15,867 | +100.0% | 0.13% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -47,814 | -100.0% | -0.15% | – |
| BRKB | Exit | BERKSHIRE HATHAWAY INC DELcl b new | $0 | – | -1,511 | -100.0% | -0.22% | – |
| TICC | Exit | TICC CAPITAL CORP | $0 | – | -31,142 | -100.0% | -0.22% | – |
| FSAM | Exit | FIFTH STR ASSET MGMT INC | $0 | – | -26,562 | -100.0% | -0.29% | – |
| ST | Exit | SENSATA TECHNOLOGIES HLDG NV | $0 | – | -10,853 | -100.0% | -0.60% | – |
| ESL | Exit | ESTERLINE TECHNOLOGIES CORP | $0 | – | -6,590 | -100.0% | -0.66% | – |
| GDX | Exit | MARKET VECTORS ETF TRgold miner etf | $0 | – | -73,274 | -100.0% | -1.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.